Q-omics provides the consensus-scored PKD1L2 profile across patient tissues and cancer cell-line models. PKD1L2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PKD1L2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PKD1L2 RNA expression shows 16,644 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where PKD1L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKD1L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKD1L2 survival associations across molecular data types. PKD1L2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKD1L2 RNA expression–survival associations across cancer types. High PKD1L2 expression shows unfavorable associations in KIRC and LUAD, but favorable associations in ACC, SKCM, CESC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PKD1L2 RNA expression.
This table summarizes PKD1L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PKD1L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKD1L2 shows lower tumor expression in COAD and BRCA and higher tumor expression in LUAD, HNSC, KIRP and KIRC. The COAD box plot shows higher PKD1L2 RNA expression in normal versus tumor tissue (log2 FC = −0.165, t-test p < 0.001).
This table shows molecular features associated with PKD1L2 in patient tissues and cancer cell lines. In patient samples, PKD1L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PKD1L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
